

Chronic obstructive pulmonary disease in over 16s: diagnosis and management

Review questions

NICE guideline

May 2018

*Commissioned by the National Institute
for Health and Care Excellence*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [2018]. All rights reserved. Subject to [Notice of rights](#).

Contents

1 Review questions	5
--------------------------	---

1 Review questions

Review Question 1	What are the most clinically and cost-effective therapies for managing complications (pulmonary hypertension and cor pulmonale) in people with stable chronic obstructive pulmonary disease (COPD)?
Review Question 2	What is the effectiveness of oxygen therapy in people with stable COPD who are mildly hypoxaemic or non-hypoxaemic at rest?
Review Question 3	In which subgroups of people is long-term oxygen therapy indicated, and is it a clinically and cost effective option for managing stable COPD in these subgroups?
Review Question 4	What is the clinical and cost effectiveness of self-management interventions, education, and telehealth monitoring for improving outcomes and adherence to treatment in people with stable COPD?
Review Question 5	In people with suspected COPD, what is the most accurate and appropriate test (for example imaging or biomarkers) to confirm the diagnosis?
Review Question 6	In people with suspected COPD, which tests (for example imaging or biomarkers) are the most accurate to identify whether they are at risk of poor outcomes and whether they will develop mild, moderate or severe COPD?
Review Question 7	In people with stable COPD, does routine assessment using a multidimensional severity assessment index (such as BODE [BMI, airflow obstruction, dyspnoea/breathlessness and exercise capacity]) better predict outcomes than forced expiratory volume in 1 second (FEV1) alone?
Review Question 8	In people with COPD, what factors (for example, viral infection) may cause an exacerbation?
Review Question 9	What is the clinical and cost effectiveness of prophylactic oral antibiotics for preventing exacerbations in people with stable COPD?
Review Question 10	In people with stable COPD, what is the clinical and cost effectiveness of a long-acting muscarinic antagonist (LAMA) plus a long-acting beta-adrenoceptor agonist (LABA) compared with: <ul style="list-style-type: none">• a LAMA alone• a LABA alone• a LABA plus an inhaled corticosteroid (ICS)?
Review Question 11	Which is the most clinically and cost-effective long-acting anticholinergic (LAMA) for managing stable COPD, and which subgroups of people should receive treatment with it?
Review Question 12	In people with stable COPD, what are the referral criteria for lung volume reduction procedures? In people with stable COPD, what are the referral criteria for bullectomy? In people with stable COPD, what are the referral criteria for lung transplantation?